KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Amortization of Deferred Charges: 2017-2024

Historic Amortization of Deferred Charges for Emergent BioSolutions (EBS) over the last 8 years, with Dec 2024 value amounting to $7.4 million.

  • Emergent BioSolutions' Amortization of Deferred Charges rose 137.31% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 13.76%. This contributed to the annual value of $7.4 million for FY2024, which is 65.26% down from last year.
  • As of FY2024, Emergent BioSolutions' Amortization of Deferred Charges stood at $7.4 million, which was down 65.26% from $21.3 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Amortization of Deferred Charges ranged from a high of $21.3 million in FY2023 and a low of $3.5 million during FY2020.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $7.4 million (2024), whereas its average is $10.9 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Amortization of Deferred Charges skyrocketed by 419.51% in 2023, and later plummeted by 65.26% in 2024.
  • Emergent BioSolutions' Amortization of Deferred Charges (Yearly) stood at $3.5 million in 2020, then increased by 17.14% to $4.1 million in 2021, then remained steady at $4.1 million in 2022, then soared by 419.51% to $21.3 million in 2023, then plummeted by 65.26% to $7.4 million in 2024.